Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi; Yamamoto, Wataru; Hashimoto, Motomu; Murata, Koichi; Takeuchi, Tohru; Shiba, Hideyuki; Son, Yonsu; Amuro, Hideki; Onishi, Akira; Akashi, Kengo; Hara, Ryota; Katayama, Masaki; Yamamoto, Keiichi; Kumanogoh, Atsushi; Hirao, Makoto

doi:https://doi.org/10.1186/s13075-020-02232-w

Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study

Ebina, Kosuke; Hirano, Toru; Maeda, Yuichi et al.

Arthritis Research and Therapy, 2020, 22(1), 142

アクセス数:113件（2025-04-06 20:59 集計）

固定URL: https://hdl.handle.net/11094/93207

閲覧可能ファイル

ファイル	フォーマット	利用条件	サイズ	閲覧回数	利用開始日	説明	information
ArthritisResTher_22_1	pdf	なし	1.35 MB	52	2023.11.28

Creative Commons : 表示

論文情報

ファイル出力 EndNote Basic出力 Mendeley出力

タイトル	Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study
著者	NRID 1000070612076 1000070612076 researchmap permalink k-ebina k-ebina Scopus Author ID 8415453300 8415453300 ORCID 0000-0002-2426-1024 0000-0002-2426-1024 著者名 Ebina, Kosuke
	NRID 1000010437402 1000010437402 Scopus Author ID 55456655500 55456655500 著者名 Hirano, Toru
	NRID 1000010815658 1000010815658 Scopus Author ID 56655338200 56655338200 著者名 Maeda, Yuichi
	著者名 Yamamoto, Wataru
	NRID 1000060512845 1000060512845 著者名 Hashimoto, Motomu
	NRID 1000060806793 1000060806793 著者名 Murata, Koichi
	NRID 1000010330078 1000010330078 著者名 Takeuchi, Tohru
	著者名 Shiba, Hideyuki
	著者名 Son, Yonsu
	著者名 Amuro, Hideki
	NRID 1000060634269 1000060634269 著者名 Onishi, Akira
	NRID 1000060792637 1000060792637 著者名 Akashi, Kengo
	NRID 1000010597107 1000010597107 著者名 Hara, Ryota
	著者名 Katayama, Masaki
	NRID 1000070416387 1000070416387 著者名 Yamamoto, Keiichi
	NRID 1000010294125 1000010294125 researchmap permalink read0051725 read0051725 Scopus Author ID 6602726311 6602726311 ORCID 0000-0003-4749-7117 0000-0003-4749-7117 著者名 Kumanogoh, Atsushi
	NRID 1000010527708 1000010527708 Scopus Author ID 8883255100 8883255100 著者名 Hirao, Makoto
キーワード等	ANSWER cohort
	Biological disease-modifying antirheumatic drugs
	Drug retention
	Rheumatoid arthritis
内容	Ebina K., Hirano T., Maeda Y., et al. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study. Arthritis Research and Therapy 22, 142 (2020); https://doi.org/10.1186/s13075-020-02232-w.
抄録	Background: This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of 7 biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF), one of the janus kinase inhibitors, in bDMARDs-naïve and bDMARDs-switched patients with rheumatoid arthritis (RA). Methods: This study assessed 3897 patients and 4415 treatment courses with bDMARDs and TOF from 2001 to 2019 (2737 bDMARDs-naïve courses and 1678 bDMARDs-switched courses [59.5% of switched courses were their second agent], female 82.3%, baseline age 57.4 years, disease duration 8.5 years; rheumatoid factor positivity 78.4%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate 4.3; concomitant prednisolone [PSL] dose 6.1 mg/day [usage 42.4%], and methotrexate [MTX] dose 8.5 mg/week [usage 60.9%]). Treatment courses included abatacept (ABT; n = 663), adalimumab (ADA; n = 536), certolizumab pegol (CZP; n = 226), etanercept (ETN; n = 856), golimumab (GLM; n = 458), infliximab (IFX; n = 724), tocilizumab (TCZ; n = 851), and TOF (n = 101/only bDMARDs-switched cases). Drug discontinuation reasons (categorized into lack of effectiveness, toxic adverse events, non-toxic reasons, or remission) and rates were estimated at 36 months using Gray's test and statistically evaluated after adjusted by potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX usage, starting date, and number of switched bDMARDs) using the Fine-Gray model. Results: Cumulative incidence of drug discontinuation for each reason was as follows: lack of effectiveness in the bDMARDs-naïve group (from 13.7% [ABT] to 26.9% [CZP]; P < 0.001 between agents) and the bDMARDs-switched group (from 18.9% [TCZ] to 46.1% [CZP]; P < 0.001 between agents); toxic adverse events in the bDMARDs-naïve group (from 4.6% [ABT] to 11.2% [ETN]; P < 0.001 between agents) and the bDMARDs-switched group (from 5.0% [ETN] to 15.7% [TOF]; P = 0.004 between agents); and remission in the bDMARDs-naïve group (from 2.9% [ETN] to 10.0% [IFX]; P < 0.001 between agents) and the bDMARDs-switched group (from 1.1% [CZP] to 3.3% [GLM]; P = 0.9 between agents). Conclusions: Remarkable differences were observed in drug retention of 7 bDMARDs and TOF between bDMARDs-naïve and bDMARDs-switched cases.
出版者	BioMed Central Ltd
収録物名	Arthritis Research and Therapy
巻(号)	22(1)
ページ	142
刊行年月	2020-12-01
言語	英語
ハンドルURL	https://hdl.handle.net/11094/93207
PISSN	14786354
eISSN	14786362
関連情報 (isIdenticalTo)	DOI (出版社版) https://doi.org/10.1186/s13075-020-02232-w
アクセス権	open access
権利情報	This article is licensed under a Creative Commons Attribution 4.0 International License.
出版タイプ	Version of Record
カテゴリ	学術雑誌論文 Journal Article

資源タイプ	学術雑誌論文
ローカル資源タイプ	学術雑誌論文
DCMI資源タイプ	text
DCTERMS.bibliographicCitation	Arthritis Research and Therapy. 2020, 22(1), p. 142
DC.title	Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study
DC.creator	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Takeuchi, Tohru
	Shiba, Hideyuki
	Son, Yonsu
	Amuro, Hideki
	Onishi, Akira
	Akashi, Kengo
	Hara, Ryota
	Katayama, Masaki
	Yamamoto, Keiichi
	Kumanogoh, Atsushi
	Hirao, Makoto
DC.publisher	BioMed Central Ltd
DC.language' scheme='DCTERMS.RFC1766	英語
DC.type' scheme='DCTERMS.DCMIType	text
DCTERMS.issued' scheme='DCTERMS.W3CDTF	2020-12-01
DC.identifier	https://doi.org/10.1186/s13075-020-02232-w
DC.subject	ANSWER cohort
	Biological disease-modifying antirheumatic drugs
	Drug retention
	Rheumatoid arthritis
DC.description	Ebina K., Hirano T., Maeda Y., et al. Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study. Arthritis Research and Therapy 22, 142 (2020); https://doi.org/10.1186/s13075-020-02232-w.
DCTERMS.abstract	Background: This multi-center, retrospective study aimed to clarify retention rates and reasons for discontinuation of 7 biological disease-modifying antirheumatic drugs (bDMARDs) and tofacitinib (TOF), one of the janus kinase inhibitors, in bDMARDs-naïve and bDMARDs-switched patients with rheumatoid arthritis (RA). Methods: This study assessed 3897 patients and 4415 treatment courses with bDMARDs and TOF from 2001 to 2019 (2737 bDMARDs-naïve courses and 1678 bDMARDs-switched courses [59.5% of switched courses were their second agent], female 82.3%, baseline age 57.4 years, disease duration 8.5 years; rheumatoid factor positivity 78.4%; Disease Activity Score in 28 joints using erythrocyte sedimentation rate 4.3; concomitant prednisolone [PSL] dose 6.1 mg/day [usage 42.4%], and methotrexate [MTX] dose 8.5 mg/week [usage 60.9%]). Treatment courses included abatacept (ABT; n = 663), adalimumab (ADA; n = 536), certolizumab pegol (CZP; n = 226), etanercept (ETN; n = 856), golimumab (GLM; n = 458), infliximab (IFX; n = 724), tocilizumab (TCZ; n = 851), and TOF (n = 101/only bDMARDs-switched cases). Drug discontinuation reasons (categorized into lack of effectiveness, toxic adverse events, non-toxic reasons, or remission) and rates were estimated at 36 months using Gray's test and statistically evaluated after adjusted by potential clinical confounders (age, sex, disease duration, concomitant PSL and MTX usage, starting date, and number of switched bDMARDs) using the Fine-Gray model. Results: Cumulative incidence of drug discontinuation for each reason was as follows: lack of effectiveness in the bDMARDs-naïve group (from 13.7% [ABT] to 26.9% [CZP]; P < 0.001 between agents) and the bDMARDs-switched group (from 18.9% [TCZ] to 46.1% [CZP]; P < 0.001 between agents); toxic adverse events in the bDMARDs-naïve group (from 4.6% [ABT] to 11.2% [ETN]; P < 0.001 between agents) and the bDMARDs-switched group (from 5.0% [ETN] to 15.7% [TOF]; P = 0.004 between agents); and remission in the bDMARDs-naïve group (from 2.9% [ETN] to 10.0% [IFX]; P < 0.001 between agents) and the bDMARDs-switched group (from 1.1% [CZP] to 3.3% [GLM]; P = 0.9 between agents). Conclusions: Remarkable differences were observed in drug retention of 7 bDMARDs and TOF between bDMARDs-naïve and bDMARDs-switched cases.
DC.rights	This article is licensed under a Creative Commons Attribution 4.0 International License.
DC.format	93207
citation_title	Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study
citation_author	Ebina, Kosuke
	Hirano, Toru
	Maeda, Yuichi
	Yamamoto, Wataru
	Hashimoto, Motomu
	Murata, Koichi
	Takeuchi, Tohru
	Shiba, Hideyuki
	Son, Yonsu
	Amuro, Hideki
	Onishi, Akira
	Akashi, Kengo
	Hara, Ryota
	Katayama, Masaki
	Yamamoto, Keiichi
	Kumanogoh, Atsushi
	Hirao, Makoto
citation_publisher	BioMed Central Ltd
citation_language	英語
citation_date	2020-12-01
citation_journal_title	Arthritis Research and Therapy
citation_volume	22
citation_issue	1
citation_firstpage	142
citation_doi	https://doi.org/10.1186/s13075-020-02232-w
citation_public_url	https://hdl.handle.net/11094/93207

Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: The ANSWER cohort study

閲覧可能ファイル

論文情報

論文詳細を表示